Microvascular obstruction in cardiac amyloidosis
Related Experiment Video
Updated: Jun 10, 2025
08:52
Author Spotlight: Developing a Translational Model for Atrial Fibrillation Research Across Species
Published on: November 21, 2023
844
Lucrezia Netti1, Adam Ioannou2, Ana Martinez-Naharro2
1Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
European Journal of Heart Failure
|October 18, 2024
Abstract
No abstract available in PubMed .
Insights
Microvascular obstruction (MVO) is prevalent in cardiac amyloidosis (CA), particularly in transthyretin CA. MVO is linked to worse outcomes in light-chain CA but not transthyretin CA, highlighting distinct disease mechanisms.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Cardiac Pathology
Background:
- Cardiac amyloidosis (CA) involves amyloid fibril deposition, disrupting myocardial and capillary structures.
- Understanding microvascular obstruction (MVO) prevalence and prognostic implications in CA is crucial.
Purpose of the Study:
- To determine the prevalence of MVO in patients with CA.
- To assess the association between MVO and prognosis in different types of CA.
Main Methods:
- Retrospective analysis of 800 patients with CA (400 AL-CA, 400 ATTR-CA).
- Evaluation of MVO presence and its correlation with clinical, imaging, and biomarker data.
- Prognostic analysis using survival data.
Main Results:
- MVO was identified in 27.6% of patients, more common in transthyretin CA (ATTR-CA) than light-chain CA (AL-CA).
- Patients with MVO exhibited a more severe cardiac phenotype, including elevated NT-proBNP and reduced global longitudinal strain.
- MVO was associated with increased mortality risk in AL-CA but not ATTR-CA.
Conclusions:
- Microvascular obstruction is a frequent finding in cardiac amyloidosis, associated with markers of amyloid infiltration.
- MVO portends a worse prognosis in AL-CA, suggesting distinct pathophysiological mechanisms compared to ATTR-CA.
- These findings underscore the heterogeneity of CA and the multifaceted role of MVO in disease progression.
Related Concept Videos
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
1
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
1
01:21Myocarditis I: Introduction
2
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
2
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:25Cardiomyopathy I: Introduction and Classification
1
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
1
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
1
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
1